RT Journal Article
T1 Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer.
A1 Aroca-Siendones, María I
A1 Moreno-SanJuan, Sara
A1 Puentes-Pardo, Jose D
A1 Verbeni, Michela
A1 Arnedo, Javier
A1 Escudero-Feliu, Julia
A1 García-Costela, María
A1 García-Robles, Adelina
A1 Carazo, Ángel
A1 León, Josefa
K1 colorectal cancer
K1 core circadian clock
K1 disease free survival
K1 local recurrence
K1 metachronous metastasis
K1 overall survival
AB Colorectal cancer (CRC) is one of the most common tumours in developed countries. Although its incidence and mortality rates have decreased, its prognosis has not changed, and a high percentage of patients with CRC develop relapse (metachronous metastasis, MM, or local recurrence, LR) during their disease. The identification of these patients is very important for their correct management, but the lack of prognostic markers makes it difficult. Given the connection between circadian disruption and cancer development and progression, we aimed to analyse the prognostic significance of core circadian proteins in CRC. We measured the expression of PER1-3, CRY1-2, BMAL1 and NR1D2 in a cohort of CRC patients by immunohistochemistry (IHC) and analysed their prognostic potential in this disease. A low expression of PER2 and BMAL1 was significantly associated with metastasis at the moment of disease diagnosis, whereas a high expression of CRY1 appeared as an independent prognostic factor of MM development. A high expression of NR1D2 appeared as an independent prognostic factor of LR development after disease diagnosis. Moreover, patients with a low expression of BMAL1 and a high expression of CRY1 showed lower OS and DFS at five years. Although these markers need to be validated in larger and different ethnic cohorts, the simplicity of IHC makes these proteins candidates for personalizing CRC treatment.
SN 2227-9059
YR 2021
FD 2021-08-06
LK https://hdl.handle.net/10668/28161
UL https://hdl.handle.net/10668/28161
LA en
DS RISalud
RD Apr 11, 2025